Etomidate

220px
220px
Etomidate
Systematic (IUPAC) name
ethyl 3-[(1R)-1-phenylethyl]imidazole- 4-carboxylate
Identifiers
CAS number	33125-97-2
ATC code	N01AX07
PubChem	667484
DrugBank	APRD00965
Chemical data
Formula	C14H16N2O2
Mol. mass	244.289 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	75%
Metabolism	Ester hydrolysis
Half life	75 min
Excretion	Renal (85%) and biliary (15%)
Therapeutic considerations
Pregnancy cat.	D (U.S.)
Legal status	POM(UK)
Routes	Intravenous

Etomidate is a short acting intravenous anaesthetic agent used for the induction of general anaesthesia and for sedation for short procedures such as reduction of dislocated joints and cardioversion. It was discovered at Janssen Pharmaceutica in 1964.

Drug class

Etomidate, a hypnotic is a carboxylated imidazole derivative. Etomidate has anesthetic and amnestic properties, but has no analgesic properties.

Uses

Etomidate is commonly used in the emergency setting as part of a rapid sequence induction to induce anesthesia or for conscious sedation. It is often used in this setting since it has a rapid onset of action and a low cardiovascular risk profile, and therefore is less likely to cause a significant drop in blood pressure than other induction agents.

In the operating room with a stable patient, anesthesiologists may choose an alternative induction agent, such as propofol, thiopental or methohexital. (see Side effects below).

At the typical dose, anesthesia is induced for about 5–10 minutes even though the half-life of drug metabolism is approximately 75 minutes. This is because etomidate is redistributed from the plasma to other tissues.

Dosage

The anaesthetic induction dose for adult humans is 0.3 mg/kg intravenously, with a typical dose ranging from 20-40 mg. In common with all induction agents, etomidate causes loss of consciousness after one arm-brain circulation time. In very brief procedures such as cardioversion, a 10 mg dose may be used which may be repeated for effect.

Metabolism

Etomidate is highly protein bound in blood plasma and is metabolised by hepatic and plasma esterases to inactive products. It exhibits a bi-exponential decline, with a redistribution half-life of 2–5 minutes and an elimination half-life of 68–75 minutes.

Side effects

The use of etomidate infusions for sedation of critically ill patients in intensive care units has been associated with increased mortality, which is due to suppression of steroid synthesis (both glucocorticoids and mineralocorticoids) in the adrenal cortex. This effect has been demonstrated after a single dose, and lasts about 24 hours. There is no evidence that a single induction dose of etomidate has any effect on morbidity or mortality. However, some sources advise giving a prophylactic dose of steroids (e.g. hydrocortisone) if etomidate is used.

Seizure-like activity is occasionally seen with anesthetic induction. In the absence of concurrent EEG monitoring, it is difficult to ascribe this to cortical activity. Myoclonic movement originating at the spinal cord level is often a likely mechanism. Excitatory phenomena, and epileptiform movements and EEG activity may be observed during induction. Etomidate consistently increases the amplitude of somatosensory evoked potentials (in contrast to most anaesthetic agents).

Etomidate in the propylene glycol formulation may produce pain on injection, a side effect which is less likely with the lipid formulation.

There is a 30-fold difference between the effective dose and the lethal dose of etomidate, making it an extremely safe agent.

Formulation

Etomidate is usually presented as a clear colourless solution for injection containing 2 mg/ml of etomidate in an aqueous solution of 35% propylene glycol, although a lipid emulsion preparation (of equivalent strength) has also been introduced. Etomidate is presented as a racemic mixture, but only the D-isomer has pharmacological activity.

de:Etomidatit:Etomidate